Kramer, Kim

Publications

Sort by

Co-Author Network

selected publications

Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. The Lancet. Oncology. 2018 Academic Article GET IT
Times cited: 209
A phase II study of radioimmunotherapy with intraventricular ¹³¹ I-3F8 for medulloblastoma. Pediatric blood & cancer. 2017 Academic Article GET IT
Times cited: 55
A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors. PloS one. 2017 Academic Article GET IT
Times cited: 34
A phase I study of perifosine with temsirolimus for recurrent pediatric solid tumors. Pediatric blood & cancer. 2016 Academic Article GET IT
Times cited: 34
Evaluating the Utility of a 'N-of-1' Precision Cancer Medicine Strategy: The Case for 'Time-to-Subsequent-Disease Progression'. Oncology. 2016 Information Resource GET IT
Times cited: 3
A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma. International journal of cancer. 2016 Academic Article GET IT
Times cited: 45
Lack of survival advantage with autologous stem-cell transplantation in high-risk neuroblastoma consolidated by anti-GD2 immunotherapy and isotretinoin. Oncotarget. 2016 Academic Article GET IT
Times cited: 55
Arsenic Trioxide as a Radiation Sensitizer for 131I-Metaiodobenzylguanidine Therapy: Results of a Phase II Study. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2016 Academic Article GET IT
Times cited: 18
Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients. OncoTargets and therapy. 2015 Academic Article GET IT
Times cited: 45
Prolonged progression-free survival after consolidating second or later remissions of neuroblastoma with Anti-G_D2 immunotherapy and isotretinoin: a prospective Phase II study. Oncoimmunology. 2015 Academic Article GET IT
Low incidence of radionecrosis in children treated with conventional radiation therapy and intrathecal radioimmunotherapy. Journal of neuro-oncology. 2015 Academic Article GET IT
Times cited: 26
When overall survival fails to confirm event-free survival, should the latter be used to set the standard of care?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Article GET IT
Times cited: 6
Initial experience with genomic profiling of heavily pretreated breast cancers. Annals of surgical oncology. 2014 Academic Article GET IT
Times cited: 3
Safety profile of long-term intraventricular access devices in pediatric patients receiving radioimmunotherapy for central nervous system malignancies. Pediatric blood & cancer. 2014 Academic Article GET IT
Times cited: 18
Key role for myeloid cells: phase II results of anti-G(D2) antibody 3F8 plus granulocyte-macrophage colony-stimulating factor for chemoresistant osteomedullary neuroblastoma. International journal of cancer. 2014 Academic Article GET IT
Times cited: 89
Striking dichotomy in outcome of MYCN-amplified neuroblastoma in the contemporary era. Cancer. 2014 Academic Article GET IT
Times cited: 37
Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission. Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Academic Article GET IT
Times cited: 119
Marker (+) CNS germ cell tumors in remission: are surveillance MRI scans necessary?. Pediatric blood & cancer. 2013 Academic Article GET IT
Times cited: 5
Posterior reversible encephalopathy syndrome in neuroblastoma patients receiving anti-GD2 3F8 monoclonal antibody. Cancer. 2013 Academic Article GET IT
Times cited: 26
Anti-GD2 antibody 3F8 and barley-derived (1 → 3),(1 → 4)-β-D-glucan: A Phase I study in patients with chemoresistant neuroblastoma. Oncoimmunology. 2013 Academic Article GET IT
5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma. Bone marrow transplantation. 2012 Academic Article GET IT
Times cited: 3
Murine anti-GD2 monoclonal antibody 3F8 combined with granulocyte-macrophage colony-stimulating factor and 13-cis-retinoic acid in high-risk patients with stage 4 neuroblastoma in first remission. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2012 Academic Article GET IT
Times cited: 231
Plerixafor plus granulocyte-colony stimulating factor for autologous hematopoietic stem cell mobilization in patients with metastatic neuroblastoma. Pediatric blood & cancer. 2011 Academic Article GET IT
Times cited: 23
High-dose carboplatin-irinotecan-temozolomide: treatment option for neuroblastoma resistant to topotecan. Pediatric blood & cancer. 2011 Academic Article GET IT
Times cited: 22
Successful multifold dose escalation of anti-GD2 monoclonal antibody 3F8 in patients with neuroblastoma: a phase I study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011 Academic Article GET IT
Times cited: 51
Variable MR imaging appearances of focal nodular hyperplasia in pediatric cancer patients. Pediatric radiology. 2010 Academic Article GET IT
Times cited: 18
Two-compartment model of radioimmunotherapy delivered through cerebrospinal fluid. European journal of nuclear medicine and molecular imaging. 2010 Academic Article GET IT
Times cited: 13
High-dose cyclophosphamide-irinotecan-vincristine for primary refractory neuroblastoma. European journal of cancer. 2010 Academic Article GET IT
Times cited: 13
Preliminary results of a phase I trial of prophylactic ethanol-lock administration to prevent mediport catheter-related bloodstream infections. Journal of pediatric surgery. 2010 Academic Article GET IT
Times cited: 39
Hypothyroidism after 131I-monoclonal antibody treatment of neuroblastoma. Pediatric blood & cancer. 2010 Academic Article GET IT
Times cited: 5
Differential impact of high-dose cyclophosphamide, topotecan, and vincristine in clinical subsets of patients with chemoresistant neuroblastoma. Cancer. 2010 Academic Article GET IT
Times cited: 30
Whole neuraxis irradiation to address central nervous system relapse in high-risk neuroblastoma. International journal of radiation oncology, biology, physics. 2010 Academic Article GET IT
Times cited: 8
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. Journal of neuro-oncology. 2009 Academic Article GET IT
Times cited: 209
Reduced risk of secondary leukemia with fewer cycles of dose-intensive induction chemotherapy in patients with neuroblastoma. Pediatric blood & cancer. 2009 Academic Article GET IT
Times cited: 39
Hyperfractionated low-dose (21 Gy) radiotherapy for cranial skeletal metastases in patients with high-risk neuroblastoma. International journal of radiation oncology, biology, physics. 2009 Academic Article GET IT
Times cited: 9
Sensitivity of surveillance studies for detecting asymptomatic and unsuspected relapse of high-risk neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 73
Large congenital melanotic nevi in an extremity with neurocutaneous melanocytosis. 2009 GET IT
Times cited: 10
Management and outcome of stage 3 neuroblastoma. European journal of cancer. 2008 Academic Article GET IT
Times cited: 38
Brain-sparing radiotherapy for neuroblastoma skull metastases. Pediatric blood & cancer. 2008 Academic Article GET IT
Times cited: 8
Transient sialoadenitis: a complication of 131I-metaiodobenzylguanidine therapy. Pediatric blood & cancer. 2008 Academic Article GET IT
Times cited: 30
Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 86
A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies. Pediatric blood & cancer. 2007 Academic Article GET IT
Times cited: 13
High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy. Pediatric blood & cancer. 2007 Academic Article GET IT
Times cited: 20
Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006 Academic Article GET IT
Times cited: 96
Ototoxicity from high-dose use of platinum compounds in patients with neuroblastoma. Cancer. 2006 Academic Article GET IT
Times cited: 100
Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system. Bone marrow transplantation. 2006 Academic Article GET IT
Times cited: 23
Epidural compression in neuroblastoma: Diagnostic and therapeutic aspects. Cancer letters. 2005 Information Resource GET IT
Times cited: 31
Long-term complications in survivors of advanced stage neuroblastoma. Pediatric blood & cancer. 2005 Academic Article GET IT
Times cited: 124
Clinical and diagnostic comparison of neonatal alloimmune thrombocytopenia to non-immune cases of thrombocytopenia. Pediatric blood & cancer. 2005 Academic Article GET IT
Times cited: 92
Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 84
Treatment of neuroblastoma meningeal carcinomatosis with intrathecal application of alpha-emitting atomic nanogenerators targeting disialo-ganglioside GD2. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 34
The impact of gross total resection on local control and survival in high-risk neuroblastoma. Journal of pediatric surgery. 2004 Academic Article GET IT
Times cited: 134
Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Academic Article GET IT
Times cited: 37
Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2004 Academic Article GET IT
Times cited: 98
Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience. Medical and pediatric oncology. 2003 Academic Article GET IT
Times cited: 62
Third meeting on Novel Adjuvants Currently in or Close to Clinical Testing World Health Organization--Organisation Mondiale de la Santé, Fondation Mérieux, Annecy, France, 7-9 January 2002. Vaccine. 2003 Conference Paper GET IT
Times cited: 24
Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis. Journal of pediatric hematology/oncology. 2003 Academic Article GET IT
Times cited: 24
Curability of recurrent disseminated disease after surgery alone for local-regional neuroblastoma using intensive chemotherapy and anti-G(D2) immunotherapy. Journal of pediatric hematology/oncology. 2003 Academic Article GET IT
Times cited: 19
Impact of metaiodobenzylguanidine scintigraphy on assessing response of high-risk neuroblastoma to dose-intensive induction chemotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 49
Quantitation of GD2 synthase mRNA by real-time reverse transcriptase polymerase chain reaction: clinical utility in evaluating adjuvant therapy in neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2003 Academic Article GET IT
Times cited: 45
Chronic neuroblastoma. Cancer. 2002 Academic Article GET IT
Times cited: 23
Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 161
Monoclonal antibody-based therapy of neuroblastoma. Hematology/oncology clinics of North America. 2001 Information Resource GET IT
Times cited: 32
Topotecan combined with myeloablative doses of thiotepa and carboplatin for neuroblastoma, brain tumors, and other poor-risk solid tumors in children and young adults. Bone marrow transplantation. 2001 Academic Article GET IT
Times cited: 50
Extending positron emission tomography scan utility to high-risk neuroblastoma: fluorine-18 fluorodeoxyglucose positron emission tomography as sole imaging modality in follow-up of patients. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 138
Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2001 Academic Article GET IT
Times cited: 99
Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer research. 2001 Academic Article GET IT
Times cited: 102
Granulocyte-colony stimulating factor and multiple cycles of strongly myelosuppressive alkylator-based combination chemotherapy in children with neuroblastoma. Cancer. 2000 Academic Article GET IT
Times cited: 17
Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Medical and pediatric oncology. 2000 Academic Article GET IT
Times cited: 61
Local control with multimodality therapy for stage 4 neuroblastoma. International journal of radiation oncology, biology, physics. 2000 Academic Article GET IT
Times cited: 63
Clinically critical impact of molecular genetic studies in pediatric solid tumors. Medical and pediatric oncology. 1999 Academic Article GET IT
Times cited: 31
Oral etoposide for refractory and relapsed neuroblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1999 Academic Article GET IT
Intrauterine fetal diagnosis for hematologic and other congenital disorders. Clinics in laboratory medicine. 1999 Information Resource GET IT
Times cited: 4
Detection of neuroblastoma in bone marrow by immunocytology: is a single marrow aspirate adequate?. Medical and pediatric oncology. 1999 Academic Article GET IT
Times cited: 12
Neuroblastoma and treatment-related myelodysplasia/leukemia: the Memorial Sloan-Kettering experience and a literature review. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Information Resource GET IT
Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
Disialoganglioside G(D2) loss following monoclonal antibody therapy is rare in neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 1998 Academic Article GET IT
Times cited: 46
High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1998 Academic Article GET IT
Pharmacokinetics and acute toxicology of intraventricular 131 I-monoclonal antibody targeting disialoganglioside in non-human primates. Journal of neuro-oncology. 1997 Academic Article GET IT
Times cited: 17
Prognostic value of TrkA protein detection by monoclonal antibody 5C3 in neuroblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 1996 Academic Article GET IT
Times cited: 14
Autologous bone marrow transplantation in children with advanced neuroblastoma. Cancer. 1995 Article GET IT
Times cited: 1

more ...

less ...

Background

education and training

M.D., State University of New York Upstate Medical University 1989
B.S., Sophie Davis School of Biomedical Education, City University of New York 1987

VIVO Weill Cornell Medical College

Kim Kramer Professor of Pediatrics

Publications

selected publications

Background

education and training

Contact

full name

primary email